However, a recent phase-2 study reported poor effectiveness of the subcutaneous administration for the treatment of patients with anti-TNF refractory JIA-associated uveitis since its primary outcome on treatment response was not completely met [15]. This evidence concerns the gene TNF and juvenile idiopathic arthritis.